Anti-MTA3 antibody [EPR12777(B)]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(5 Publications)
Rabbit Recombinant Monoclonal MTA3 antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 5 publications.
View Alternative Names
KIAA1266, MTA3, Metastasis-associated protein MTA3
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-MTA3 antibody [EPR12777(B)] (AB176346)
Intracellular flow cytometric analysis of permeabilized Ramos cells labeling MTA3with ab176346 at 1/10 dilution (red)or a rabbit IgG (negative) (green).
- WB
Supplier Data
Western blot - Anti-MTA3 antibody [EPR12777(B)] (AB176346)
All lanes:
Western blot - Anti-MTA3 antibody [EPR12777(B)] (ab176346) at 1/1000 dilution
Lane 1:
T47D cell lysate at 10 µg
Lane 2:
HeLa cell lysate at 10 µg
Lane 3:
MCF7 cell lysate at 10 µg
Lane 4:
Ramos cell lysate at 10 µg
Predicted band size: 68 kDa
false
- WB
CiteAb
Western blot - Anti-MTA3 antibody [EPR12777(B)] (AB176346)
MTA3 western blot using anti-MTA3 antibody [EPR12777(B)] ab176346. Publication image and figure legend from Xiaomeng, F., Lei, L., et al., 2020, Braz J Med Biol Res, PubMed 32401925.
ab176346 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab176346 please see the product overview.
Effect of β-elemene+paclitaxel on migration (A) andinvasion (B) of SKOV3 cells (magnification bar, 100 μm).C and D, Relative E-cadherin and MTA3 mRNA(C) and protein (D) expression in SKOV3cells after treatment with β-elemene and/or paclitaxel. Data arereported as means±SD. **p<0.01 (ANOVA followed by Tukey's multiplecomparison post hoc test). ns : not significant.
false
Related conjugates and formulations (1)
-
Anti-MTA3 antibody [EPR12777(B)] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Activities involving gene expression regulation occur through interactions with other chromatin-associated molecules. MTA3 participates as a component of the NuRD complex which also includes Mi2 and HDAC1 that is critical in chromatin remodeling and transcriptional repression. Through MTA3's involvement the complex influences cell proliferation differentiation and epithelial-mesenchymal transition (EMT).
Pathways
MTA3 is particularly significant in the EMT pathway affecting cell migration and invasion capacities. It interacts with proteins such as TWIST and ZEB1 which are associated with EMT. Additionally MTA3 plays a role in the Notch signaling pathway where it helps in maintaining proper cell lineage differentiation by modulating transcription factors through deacetylation processes.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (5)
Recent publications for all applications. Explore the full list and refine your search
The Journal of biological chemistry 299:104662 PubMed36997086
2023
Applications
Unspecified application
Species
Unspecified reactive species
Brazilian journal of medical and biological resear 53:e8885 PubMed32401925
2020
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 19:3190-3200 PubMed30816482
2019
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 16:2143-2150 PubMed30008912
2018
Applications
Unspecified application
Species
Unspecified reactive species
Autophagy 11:2309-22 PubMed26735435
2016
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com